

31. (amended) An isolated DNA of claim 30, wherein said DNA additionally encodes an antibody Fc polypeptide fused to the C-terminus of said [soluble human 4-1BB] polypeptide.
32. (amended) A [recombinant expression] vector comprising a DNA according to claim 29[operably linked to regulatory sequences suitable for expression of said DNA sequence in a host cell].
33. (amended) A [recombinant expression] vector comprising a DNA according to claim 30[operably linked to regulatory sequences suitable for expression of said DNA sequence in a host cell].
34. (amended) A [recombinant expression] vector comprising a DNA according to claim 31[operably linked to regulatory sequences suitable for expression of said DNA sequence in a host cell].
35. (amended) A process for preparing a [human 4-1BB] polypeptide, comprising culturing a host cell comprising a vector according to claim 32 under conditions that promote expression of the [human 4-1BB] polypeptide[, and purifying said polypeptide].
36. (amended) A process for preparing a [soluble human 4-1BB] polypeptide, comprising culturing a host cell comprising a vector according to claim 33 under conditions that promote expression of the [human 4-1BB] polypeptide[, and purifying said polypeptide].
37. (amended) A process for preparing a fusion protein comprising an antibody Fc polypeptide fused to the C-terminus of a [soluble human 4-1BB] polypeptide, comprising culturing a host cell comprising a vector according to claim 34 under conditions that promote expression of the [human] fusion protein[, and purifying said fusion protein].
38. (amended) A purified [human 4-1BB] polypeptide comprising the N-terminal amino acid sequence Leu-Gln-Asp-Pro-Cys-Ser-Asn-Cys-Pro-Ala-Gly-Thr- (amino acid residues 1-12 of SEQ ID NO:8), the polypeptide being capable of binding 4-1BB-L.

39. (amended) A purified [4-1BB according to claim 38] polypeptide, comprising an amino acid sequence selected from the group consisting of amino acids 1-232 of SEQ ID NO:8 and amino acids 1-163 of SEQ ID NO:8.
40. (amended) A purified [4-1BB according to claim 38] polypeptide, comprising an amino acid sequence that is identical to a sequence selected from the group consisting of amino acids 1-232 of SEQ ID NO:8 and amino acids 1-163 of SEQ ID NO:8, except for conservative amino acid substitution(s).
41. (amended) A purified [soluble human 4-1BB polypeptide, wherein said polypeptide is] polypeptide selected from the group consisting of polypeptides comprising amino acids 1-163 of SEQ ID NO:8 and polypeptides comprising a fragment of amino acids 1-163 of SEQ ID NO:8, the fragment capable of binding a 4-1BB-L.
42. (amended) A purified [soluble human 4-1BB] polypeptide of claim 41, additionally comprising an antibody Fc polypeptide fused to the C-terminus of said [human 4-1BB] polypeptide.
43. (amended) A dimer comprising two [soluble human 4-1BB] polypeptides of claim [42] 41, joined *via* disulfide bonds between [the] antibody Fc polypeptides fused to said [soluble 4-1BB] polypeptides.
44. (amended) A composition comprising a [soluble human 4-1BB] polypeptide of claim 41 in admixture with a diluent, carrier, or excipient.
47. (amended) An isolated polynucleic acid [molecule] comprising [a sequence of] at least about 30 nucleotides of a DNA [sequence] according to claim 29 or its DNA or RNA complement.
48. (amended) A purified [4-1BB] polypeptide comprising amino acids 1-232 of SEQ ID NO:8.
49. (amended) A purified [4-1BB] polypeptide comprising amino acids 1-163 of SEQ ID NO:8.

REMARKS

Applicants respectfully request entry of the foregoing amendment in which claims 29-44 and 47-49 are amended. Support for the amendment is found in the claims as filed and